Related Experiment Video
Updated: Apr 20, 2026

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
[New Developments in CKD-MBD. The present state and problem of CKD-MBD treatment in Japan]
1Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Japan./Department of Internal Medicine, University of Texas, Southwestern Medical Center, USA.
Insights
CKD-MBD treatment in Japan faces challenges due to clinical factors and insurance systems. Addressing phosphate binders, severe secondary hyperparathyroidism, and osteoporosis is crucial for improved patient care.
Area of Science:
- Nephrology
- Endocrinology
- Public Health
Background:
- Japan's clinical context for Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) includes a high prevalence of long-term hemodialysis patients and limited renal transplantation.
- National differences in insurance systems, such as Japan's universal public insurance, impact medical practices and treatment accessibility for CKD-MBD.
Purpose of the Study:
- To re-evaluate the current state of CKD-MBD treatment in Japan.
- To identify and discuss unresolved issues and future challenges in optimizing CKD-MBD therapy within the Japanese healthcare system.
Main Methods:
- Review of current clinical practices and treatment guidelines for CKD-MBD in Japan.
- Analysis of the influence of specific healthcare system characteristics on treatment decisions.
Main Results:
- Key issues include selecting optimal phosphate binders and determining the best treatment strategy for severe secondary hyperparathyroidism (cinacalcet vs. surgery).
- Further considerations involve the appropriate use of native vitamin D agents and managing osteoporosis in Chronic Kidney Disease (CKD) patients.
Conclusions:
- Current CKD-MBD management in Japan requires addressing specific therapeutic choices and patient population characteristics.
- Developing more sophisticated and effective CKD-MBD therapies tailored to Japan's unique healthcare landscape is essential.
Abstract:
When considering the CKD-MBD treatment of our country, we should take account of clinical background, such as a high ratio of long-term hemodialysis patients, a small number of renal transplantation surgeries, etc. Furthermore, insurance systems differ from country to country and the universal public insurance system will also have some influences on medical circumstances in Japan. Re-considering the CKD-MBD treatment of Japan from these perspectives, there remain some issues to be addressed ; a choice of which phosphate binder is the best, a selection of treatment for severe secondary hyperparathyroidism, cinacalcet or surgery. The issues about native vitamin D agent and the treatment for osteoporosis in CKD patients should be also resolved. This article argues the present situation of CKD-MBD treatment and considers new issues and problems for more sophisticated CKD-MBD therapy in Japan.
Related Concept Videos
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease IV: Nursing Management
Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease I: Introduction
Acute Kidney Injury V: Interprofessional Care
Acute Kidney Injury VI: Nursing Management
